Daily Brief Health Care: Zhejiang Jingxin Pharmaceutical, Junshi Biosciences, IDEXX Laboratories, Docquity, MapLight Therapeutics, Ultragenyx Pharmaceutical, Lakewood-Amedex Biotherapeutics, GeoVax Labs and more

• Zhejiang Jingxin Pharmaceutical is a group focused on CNS, cardiovascular, and cerebrovascular diseases, generating revenue from drugs, APIs, medical equipment, seeking a primary HKEX listing.
• Sole approved innovative drug, Dimdazenil, launched in 2024 for insomnia. Operates eleven manufacturing facilities, with largest customer accounting for 17.2% of revenue.
• Revenue was RMB4,069,361 and profit RMB771,731 in 2025. Profit for the period decreased by 10.0% to RMB358.0 million (six months ended June 30, 2026).

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• Junshi Biosciences (1877 HK) reported stellar performance for 1H26, with the company reporting its maiden net profit. Steady revenue growth of toripalimab led to breakthroughs in revenue and profit.
• Tuoyi is reporting increasing revenue in China, driven by continued expansion of indications and NRDL coverage. 2Q26 represents 11th consecutive quarter of sequential revenue increase for Tuoyi.
• Continued clinical advancement of core pipelines, including bispecific antibody candidate, JS207 and ADC candidate, JS212 with strong clinical trial data for various types of solid tumors enhance visibility beyond toripalimab.  

• IDEXX Laboratories has moved deeper into veterinary artificial intelligence with its September 16, 2026 acquisition of CoVetAI, an AI-native clinical workflow platform designed to automate documentation, organize patient information, and streamline communication across veterinary practices.
• Financial terms were not disclosed, but the strategic logic extends beyond simply adding an ambient scribe product.
• CoVetAI will be integrated into IDEXX’s broader software, diagnostics, and AI ecosystem while continuing to support non-IDEXX practice management systems and third-party integrations.

• Dominant Regional Medical Network: Docquity has established a verified digital community of healthcare professionals across Southeast Asia and the Middle East, scaling to over 500,000 users. By providing essential continuing medical education and peer collaboration tools, the platform has secured a highly engaged digital community of healthcare professionals across Southeast Asia, North Asia and the Middle East, scaling to over 500,000 users.
• Enterprise Monetisation Engine: The core investment case rests on the company’s transition from a pure networking utility to an artificial intelligence-driven intelligence layer for life sciences companies. By monetising physician engagement signals through its data and insights offering, formalised in January 2026 as the Docquity Engage™ intelligence engine, Docquity captures recurring revenue from multinational pharmaceutical clients, having grown operating revenue by 29.7% year-on-year to US$5.2m in FY24.
• Escalating Financial Losses: The company remains loss-making at the operating level and reported a pre-tax loss of US$61.1m in FY24, although this figure is dominated by non-cash revaluations of preference shares classified as debt. The same revaluations lifted total liabilities to US$96.6m, while cash more than halved during FY24 as operations continued to consume funds, leaving the business reliant on further external capital

• MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing therapeutics for central nervous system disorders. This prospectus registers shares for resale by selling stockholders, with no proceeds for the company.
• MapLight Therapeutics has lead candidate ML-007C-MA for schizophrenia and ADP, with Fast Track designation and positive Phase 2 results. ML-004 for ASD also had topline Phase 2 results.
• The company has incurred substantial losses since inception and anticipates increasing losses, potentially never achieving or maintaining profitability in the future.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• Ultragenyx Pharmaceutical suddenly has a new story for Wall Street.
• Shares closed 13% higher at $14.50 after the FDA approved Fayuvi, a one-time gene therapy for pediatric patients with Sanfilippo syndrome Type A, a rare inherited disorder that progressively damages the brain and nervous system.
• The approval is notable because families previously had no FDA-approved treatment designed to address the underlying cause of the disease.

• Lakewood-Amedex Biotherapeutics Inc. is a biotechnology company developing novel antimicrobials for infectious diseases, especially antibiotic-resistant strains. The company will not receive proceeds from this prospectus’s share resale.
• Lakewood-Amedex has 74 issued and 27 pending patent applications as of August 2026, with lead product Nu-3 advancing to Phase 2a clinical study.
• As of December 31, 2025, the company reported an accumulated deficit of $53.4 million. The auditor expressed substantial doubt about its going concern ability.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• MVA Platform Commercial Feasibility: While Modified Vaccinia Ankara (MVA) viral vectors offer superior thermal stability and robust T-cell immunity compared to mRNA, their commercial viability is severely constrained by complex cell-based manufacturing economics and the entrenched global monopoly of Bavarian Nordic’s Jynneos (marketed as Imvanex or Imvamune), which commands a price of approximately $100 per dose.
• Extreme Capital Constraints: GeoVax is operating on a microscopic cash balance of $3,143,422 as of June 30, 2026, which provides a runway extending only into October 2026. To survive, the company is entirely dependent on shareholder approval at the October 27, 2026 special meeting to authorize a highly dilutive 11,395,256-share warrant exercise at $0.64 per share to raise $7.29 million gross, alongside a reverse stock split between 1-for-10 and 1-for-25 to avoid Nasdaq delisting.
• High-Risk Phase 3 Pivot: Following the devastating April 11, 2025 BARDA “Stop Work Order” and subsequent termination of the $45 million GEO-CM04S1 COVID-19 program, GeoVax has completely pivoted to the 500-participant GEO-MVA-301 Phase 3 immunobridging trial for mpox and smallpox. Despite operational progress, including a September 14, 2026 agreement with the CEPI Centralised Laboratory Network, executing this trial under current capital constraints and listing deficiencies remains a highly precarious proposition.